Merck & Co. recently reported one of the first mRNA display-derived clinical candidates in a bioavailable inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). Herein, we discuss the chemical and pharmacological challenges surmounted in bringing this compound to trials and the current outlook for mRNA display-based therapeutic development.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465826 | PMC |
| http://dx.doi.org/10.1021/acsmedchemlett.2c00319 | DOI Listing |
Publication Analysis
Top Keywords
mrna display
4
display reaches
4
reaches clinic
4
clinic pcsk9
4
pcsk9 inhibitor
4
inhibitor merck
4
merck reported
4
reported mrna
4
mrna display-derived
4
display-derived clinical
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!